Assembly Biosciences, Inc. (ASMB) News

Assembly Biosciences, Inc. (ASMB): $15.13

0.14 (+0.93%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ASMB to Watchlist
Sign Up

Filter ASMB News Items

ASMB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ASMB News From Around the Web

Below are the latest news stories about ASSEMBLY BIOSCIENCES INC that investors may wish to consider to help them evaluate ASMB as an investment opportunity.

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023. The Company granted Dr. Gaggar non-qualified stock options to purchase 500,000 shares of the Company’s common stock with an exercise price of $0.85 per share, the closing pri

Yahoo | November 10, 2023

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Li

Yahoo | November 10, 2023

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical development by the end of 2024Named Anuj Gaggar, MD, PhD, as chief medical officer $100 million upfront payment and investment received from Gilead in October extends projected cash runway into 2H 2025 SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: A

Yahoo | November 8, 2023

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar i

Yahoo | November 8, 2023

Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?

Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement!

William White on InvestorPlace | October 17, 2023

Why Are Stocks Down Today?

Stocks are down today, and investors wondering why are in the right place as we have all the details they need to know about on Tuesday!

William White on InvestorPlace | October 17, 2023

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., October 17, 2023--Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Yahoo | October 17, 2023

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming Americ

Yahoo | October 11, 2023

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies planned by the end of 2024 – SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-6250

Yahoo | October 2, 2023

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple

Yahoo | September 19, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!